Being Tested in Combination with MSD's anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab)

CAMBRIDGE, United Kingdom, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been dosed in its advanced melanoma (MELODY-1) trial. This international trial is due to recruit up to 40 patients at clinical centres in the UK, France, Italy and Spain. Initial data readouts are expected by the end of 2025.